
Biotechnology • Pharmaceuticals
Amylyx Pharmaceuticals is a company dedicated to discovering and developing innovative treatments for diseases with high unmet needs. They focus on conditions such as Amyotrophic Lateral Sclerosis (ALS), Post-Bariatric Hypoglycemia (PBH), Wolfram Syndrome, and Progressive Supranuclear Palsy (PSP). Amylyx is committed to supporting patients and their loved ones, creating more moments of significance for them. They have recently acquired a Phase 3-ready GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation and have shown positive results in clinical trials for Wolfram syndrome. The company emphasizes transparency, setting realistic expectations, and collaborating to make impactful changes in the treatment of neurodegenerative diseases.
201 - 500 employees
Founded 2020
🧬 Biotechnology
💊 Pharmaceuticals
November 18
Vice President of Biostatistics at Amylyx Pharmaceuticals leading statistical analysis for clinical studies. Overseeing and guiding biostatistics team, ensuring study designs meet regulatory needs.
July 30
Join Amylyx Pharmaceuticals as Medical Director, Clinical Development, driving late-stage clinical programs.